INTRODUCTION
============

The blockage and reflow of blood in the liver during transplantation causes ischemia--reperfusion (I/R) injury, which is a challenge for successful outcome. Reoxygenation after oxygen shortage in the liver increases the levels of cellular reactive oxygen species (ROS) and initiates tissue injury ([@b10-molce-42-9-672]; [@b11-molce-42-9-672]). Carbonyl reductase 1 (CBR1), a member belonging to the family of short-chain dehydrogenase/reductases, catalyzes reactions involving many biologically and pharmacologically active carbonyl substrates ([@b16-molce-42-9-672]; [@b33-molce-42-9-672]). Under oxidative stress during I/R injury, ROS drive lipid peroxidation by producing compounds with carbonyl functional groups including aldehydes and ketones, which are known to be highly reactive and potentially toxic to the cellular environment ([@b28-molce-42-9-672]; [@b33-molce-42-9-672]). Interestingly, several studies report that CBR1 decreases the formation of lipd peroxides, thereby protecting cells from I/R injury ([@b34-molce-42-9-672]; [@b36-molce-42-9-672]; [@b38-molce-42-9-672]).

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master transcription factor that regulates antioxidant production to maintain cellular redox homeostasis ([@b19-molce-42-9-672]). Under normal circumstances, Nrf2 is located in the cytoplasm and degraded by its repressor Kelch-like erythroid-associated protein 1 (Keap1) via the ubiquitin--proteasome pathway ([@b15-molce-42-9-672]). Under pathological conditions, the interaction between Keap1 and Nrf2 is disrupted, leading to Nrf2 activation. Activated Nrf2 is translocated into the nucleus, where it heterodimerizes with Maf ([@b9-molce-42-9-672]). The heterodimer binds to the antioxidant response element (ARE) promoter regions, inducing transcription of many cytoprotective and antioxidative genes, including NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1) ([@b1-molce-42-9-672]; [@b18-molce-42-9-672]; [@b19-molce-42-9-672]). While the upregulation of Nrf2 decreases I/R injury, the underlying mechanism is unclear ([@b23-molce-42-9-672]).

Based on our previous finding that Nrf2 directly regulates CBR1 transcription via the ARE region upstream of the CBR1 gene ([@b30-molce-42-9-672]), we suggest that CBR1 is a potential therapeutic target for attenuation of hepatic I/R injury under the control of Nrf2. The functions of CBR1, in particular its tissue-specific activity and the protective mechanism, remain unknown. Here, we elucidated the function of CBR1 during oxidative stress and I/R using pharmacologic studies in tissue culture, animal experiments, and clinical investigations of living-donor liver biopsies.

MATERIALS AND METHODS
=====================

Cell culture
------------

HepaRG (HPRGC10; Life Technologies, USA) cells were cultured in William's E Medium (12551-032; Life Technologies) containing HepaRG Thaw, Plate, & General Purpose Medium Supplement (HPRG770; Life Technologies) and GlutaMAX Supplement (35050-061; Life Technologies). The cells were maintained in a humidified 37°C incubator (21% O~2~ and 5% CO~2~, MCO-15AC; SANYO Electric, Japan).

Oxygen-glucose deprivation and recovery (OGD/R) and hydrogen peroxide treatment
-------------------------------------------------------------------------------

HepaRG cells were subjected to OGD/R using a humidified incubator with oxygen regulation up to 7 h followed by 2 h of reoxygenation. Briefly, the medium of HepaRG cells was replaced with glucose and sodium pyruvate-free DMEM (Thermo Fisher Scientific, USA) prior to inducing low-oxygen culture conditions. The glucose-deprived cells were exposed to hypoxic conditions (1% O~2~, 5% CO~2~, and 94% N~2~) in a multi-gas incubator (MCO-18M; SANYO Electric). The cells were washed with phosphate-buffered saline (PBS), replaced with normal culture medium, and maintained in 21% O~2~ conditions for 2 h. For hydrogen peroxide (H~2~O~2~) treatment, HepaRG cells were treated with hydrogen peroxide (200 μM, H1009; Sigma-Aldrich, USA) up to 7 h.

Immunofluorescence staining
---------------------------

HepaRG cells were seeded onto poly-L-lysine coated glass (GG-18-PLL; Neuvitro, USA) and treated OGD for 7 h followed by 2 h of recovery. After washing with ice-cold PBS 3 times, cells were fixed with 4% formaldehyde. Cells were permeabilized in PBS with 0.2% NP-40, 1% bovine serum albumin (BSA), and 0.1% sodium azide and washed 3 times with ice-cold PBS. The primary antibody, anti-CBR1 (1:100, ab156590; Abcam, UK), was diluted into PBS with 1% BSA and 0.1% NP-40 for 10 min, followed by incubation with the secondary antibody, anti-rabbit IgG-FITC (1:100, sc-2012; Santa Cruz Biotechnology, USA). After washing with PBS 3 times, cells were mounted using DAPI mounting solution (ab104139; Abcam). All images were observed under a fluoroscopic microscope (AxioObserver Z1; Carl Zeiss, Germany).

Luciferase reporter gene assay
------------------------------

HepaRG cells were seeded on a 12-well plate with 1.0 × 10^6^ cells per well and transfected with 1 μg of pRL-SV40 and 3 μg of either a pGL4.20 backbone or similar vectors containing CBR1 promoters. The pGL4.20 Basic, pGL4.20-2062, pGL4.20-412, and pGL4.20-412-mutant vectors were designed as previously described ([@b30-molce-42-9-672]). Lipofectamine 2000 (11668-019; Thermo Fisher Scientific) was used for transfection. After transfecting luciferase vectors, the cells were exposed to either OGD conditions for 7 h followed by 2 h of recovery or 200 μM of hydrogen peroxide for 7 h. Luciferase assay was conducted using the Promega dual-luciferase reporter assay system (E1910; Promega, USA) following the manufacturer's instructions. The GloMax 96 microplate luminometer (Promega) was used to detect the activity.

Stable cell line transfection
-----------------------------

HepaRG cells were transfected with pcDNA3-CBR1 wild type (CBR1/WT) or pcDNA3-basic using the lipofectamine 2000 system (Thermo Fisher Scientific). Stable cell lines were established as described previously ([@b38-molce-42-9-672]). Briefly, the transfected HepaRG cells were maintained in a culture medium treated with G418 disulfate salt (600 mg/ml, A1720; Sigma-Aldrich), and G-418 resistant colonies were selected.

RNA interference
----------------

Small interfering RNAs (siRNA) specific to either CBR1 (CBR1-siRNA) or a scrambled sequence (scrambled-siRNA) were prepared by Bioneer (Korea). Cells were transfected with siRNA (0.5 μg) using Lipofectamine 2000 (Thermo Fisher Scientific). The siRNA target sequences were as follows: CBR1-siRNA sense, 5′-rCrArCrArGArAUUrArCUrCrCrCUrCUrCUrATT-3′; antisense, 5′-UrA rGrArGrGrArGUrArAUUrCUrGUrGTT-3′; scrambled-siRNA sense, 5′-UCCCAGAUAGAGACUUCAATT-3′; scrambled-siRNA antisense, 5′-UUGAAGUCUCUAUCUGGGATT-3′. The efficiency of siRNA-based interference with CBR1 synthesis was assessed by quantitative real time-polymerase chain reaction (qRT-PCR) and western blot.

Ischemia-reperfusion (I/R) animal model
---------------------------------------

Male C57BL/6 mice (8 weeks of age) were purchased from Orient Bio (Korea). Mice were maintained at 22°C ± 2°C, relative humidity 50% to 60%, under a 12-h/12-h light--dark cycle. To monitor time-dependent changes in I/R injury, mice were divided into 4 groups (sham, 2 h reperfusion, 6 h reperfusion, and 24 h reperfusion; n = 6 per group). All mice were anesthetized via intraperitoneal injection of a mixture of Zoletil 50 (0.15 ml/kg; Virbac, France) and Rompun (0.3 ml/kg; Bayer Korea, Korea) diluted in saline. To induce partial hepatic ischemia, an 11-mm long micro-clamp (00398-02; Fine Science Tools, USA) was used to obstruct the portal vein for 45 min and removed. Mice were sacrificed after reperfusion for 2 h, 6 h, or 24 h.

To observe drug-related phenotypic changes in I/R injury, mice were randomly divided into 8 groups (n = 6--12 per group). Mice were treated with either sulforaphane (SF, Cat\#14797; Cayman Chemical Company, USA) or luteolin (LT, Cat\#10004161; Cayman Chemical Company). SF was dissolved in saline and administered to mice (50 mg/kg body weight intraperitoneally). As LT did not dissolve in the saline, Polyoxyl 35 castor oil (also known as Kolliphor EL; BASF, Germany) was used as an emulsifier. LT was dissolved in saline containing 8% w/v Kolliphor EL and orally administrated to the mice (100 mg/kg body weight). Sham and I/R groups with SF and LT were treated with corresponding vehicles. Vehicles or SF and LT were administered 48 h and 24 h before starting the hepatic I/R protocol. Mice undergoing hepatic I/R injury were exposed to 45 min of ischemia followed by 6 h of reperfusion using the methods described above. All animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the Asan Institute for Life Sciences at the Asan Medical Center (protocol No. 2015-04-172).

Serum chemistry
---------------

Whole blood samples were obtained from the inferior vena cava of the mice. All whole blood samples were collected in serum separator tubes (SSTs) (BD, USA) and incubated for 30 min at room temperature (22°C ± 2°C). After coagulation, SSTs were centrifuged at 4,000*g* for 10 min at 4°C. The clear supernatants were collected and stored as serum samples. Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) were measured using a Hitachi 7180 autoanalyzer (Hitachi, Japan).

Immunohistochemistry
--------------------

Liver tissues were harvested, fixed in 4% formalin solution, and embeded in paraffin. The paraffin blocks were cut into 2-μm sections and attached to glass slides. After removing the paraffin, the pre-fixed tissues were stained with H&E solution. Damage was scored by three pathologists using the Suzuki method based on the presence and/or severity of sinusoidal congeston, cytoplasmic vacuolization, and necrosis of parnechymal cells (score range, 0--4). Another set of sections (thickness, 4 μm) was procesed using anti-CBR1 antibody (1:500, ab186825; Abcam). Liver tissue was harvested following 6 h of reperfusion and stained as previously described. Sections were stained with H&E. Examination and scoring (Suzuki scoring, 0--4) based on the presence and/or severity of sinusoidal congestion, cytoplasmic vacuolization, and necrosis of parenchymal cells were performed with six representative sections of each liver sample in a blinded fashion.

Patient tissue samples
----------------------

Liver tissues were obtained from patients undergoing living-donor liver transplantation who visited Asan Medical Center and provided written consent. Liver biopsies (-- I/R) were obtained at the end of the cold ischemia time (CIT) during preparation of the donor liver. A second biopsy (+ I/R) was obtained immediately before closure of the abdomen following drain placement. Importantly, the total reperfusion time (RT) was defined as the time from portal vein perfusion to abdominal closure at the conclusion of the procedure. Patient characteristics are described on [Table 1](#t1-molce-42-9-672){ref-type="table"}. The collection and use of patient samples were approved by the Asan Medical Center Institutional Review Board (AMC IRB) (approval No. 2016-0582).

Western blot analysis
---------------------

HepaRG cells (2.0 × 10^6^ cells) or 25--30 mg of liver tissues were obtained for further processing. Cytoplasmic and nuclear extracts were collected separately using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) including a protease inhibitor (Roche Diagnostics, Germany) following the manufacturer's instructions. The protein concentration was measured using the bicinchoninic acid (BCA) method with 2 mg/ml BSA as the standard (Thermo Fisher Scientific). Equal amounts of protein were separated by 10% SDS-PAGE. The separated proteins were transferred onto nitrocellulose membranes. The membranes were blocked with 5% BSA in Tris-buffered saline with 0.1% Tween-20 (TBST, pH 7.6) for 1 h at room temperature (22°C--24°C), followed by incubation with the appropriate primary antibody overnight at 4°C and incubation with a secondary antibody for 1 h at room temperature. All antibodies were diluted in TBST (pH 7.6). Primary antibodies against NRF2 (1:1,000, ab62352; Abcam), TBP (1:1,000, sc-421; Santa Cruz Biotechnology), CBR1 (1:1,000, ab174852; Abcam), HSP70 (1:2,000, 610608; BD Biosciences, USA), and HSP60 (1:2,000, 611562; BD Biosciences) were used. Other compounds such as 4-hydroxynonenal (4HNE, 1:1000; LifeSpan Biosciences, USA), MDA (1:1,000, ALX-210-879; Enzo Life Sciences, USA), and Acrolein (1:1,000, LS-C63521; LifeSpan Biosciences) were also used. The nitrocellulose membranes were washed 3 times with TBST (pH 7.6) for 10 min at room temperature and incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (Rabbit-IgG, 1:5,000, sc-2004; Mouse-IgG, 1:5,000, sc-2005; Santa Cruz Biotechnology). The membranes were washed five times with TBST for 10 min at room temperature. Membranes were treated with the chemiluminescence reagent SuperSignal West Femto Substrate (Thermo Fisher Scientific) and detected using the Image Quant LAS-4000 imaging system (GE Healthcare Life Sciences, USA). Western blot image was quantified using Image Studio Lite 5.0 (LI-COR Biosciences, USA). Protein levels were normalized to Actin, except for Nrf2 which was normalized to TBP. The levels of other compounds were normalized to matching control group.

Quantitative real-time PCR
--------------------------

Total RNAs were collected using Qiazol lysis reagent (Qiagen, Germany) and RNeasy mini kit (Qiagen) using a modified protocol. In short, HepaRG cells (2.0 × 10^6^ cells) or 25--30 mg of liver tissues were treated with 0.5 ml of Qiazol lysis buffer and were collected, mixed with 0.1 ml of chloroform and centrifuged in a refrigerated centrifuge at the highest speed for 10 min. The clear supernatants were separately collected and the nucleic acids were precipitated using 70% ethanol. The precipitated total RNAs were bound on the silica column of RNeasy mini kit components, washed twice with RPE buffer (provided in the kit), and eluted with RNase-free distilled water (provided in the kit).

The concentration and quality of the extracted RNA were measured using Nanodrop2000 (Thermo Fisher Scientific). Samples with optical density 260/280 value above 1.8 were used for further experiments. The cDNA was generated from the mRNA using the ReverTra Ace qPCR RT Master Mix (Toyobo, Japan). The transcripts were quantified by real-time reverse transcription-polymerase chain reaction (RT-PCR) using the CFX Connect Real-Time PCR Detection System (Bio-Rad, USA) with 5× HOT FIREPol EvaGreen qPCR Supermix (Solis BioDyne, Estonia). The samples were first denatured at 95°C for 15 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 55°C--60°C for 15 s, and elongation at 72°C for 20 s. The data were expressed as the fold change in the treatment groups relative to the control and normalized to *GAPDH* levels. The primer sequences are shown in [Table 2](#t2-molce-42-9-672){ref-type="table"}.

Statistical analysis
--------------------

All statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad Software, USA). Liver injury score data were presented as the median and range. All other data were presented as the mean ± SD. Statistical analyses were performed using ANOVA followed by Bonferroni's multiple comparison test; the exact *P* value (when *P* \> 0.001 but \< 0.05) or the highest *P* value (*P* \< 0.001) were described.

RESULTS
=======

OGD/R and hydrogen peroxide treatment both induces CBR1 transcription via Nrf2
------------------------------------------------------------------------------

To investigate whether Nrf2 increased the CBR1 transcription, we treated HepaRG, the normal hepatocyte cells OGD/R or hydrogen peroxide for up to 7 h. In response to OGD/R and hydrogen peroxide treatment, the expression of both CBR1 and Nrf2 was increased in quantified western blot analysis ([Figs. 1A--1D](#f1-molce-42-9-672){ref-type="fig"}). To determine whether OGD/R and hydrogen peroxide-induced CBR1 expression requires Nrf2, we investigated the CBR1 promoter region up to −2,000 bp from the transcription start site ([Fig. 1E](#f1-molce-42-9-672){ref-type="fig"}). We found two putative Nrf2-binding regions matching the ARE (TGACXXXGC consensus sequence), located at −615 bp and −252 bp upstream. We found that pGL4.20-CBR1-2062 and pGL4.20-CBR1-412 showed high luciferase activity under OGD/R, while a pGL4.20-CBR1-ARE1 mutant containing 5′-*G*GACTTTGCA-3′, instead of 5′-TGACTTTGCA-3′ at the ARE exhibited limited luciferase activity ([Figs. 1F and 1G](#f1-molce-42-9-672){ref-type="fig"}). Immunofluorescence staining using a CBR1 monoclonal antibody revealed that CBR1 was strongly induced by OGD/R ([Fig. 1H](#f1-molce-42-9-672){ref-type="fig"}).

CBR1 expression increases during murine hepatic I/R in a time-dependent manner
------------------------------------------------------------------------------

The time course of animal experiment was measured during partial hepatic I/R in WT mice ([Fig. 2A](#f2-molce-42-9-672){ref-type="fig"}). The serum AST and ALT levels peaked after reperfusion for 6 h ([Figs. 2B and 2C](#f2-molce-42-9-672){ref-type="fig"}). Similar patterns of tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) transcription were detected in the damaged liver ([Figs. 2D and 2E](#f2-molce-42-9-672){ref-type="fig"}). These results were confirmed by qRT-PCR, with CBR1 expression increasing in a time-dependent manner, peaking after 6 h of reperfusion and decreasing significantly thereafter ([Fig. 2F](#f2-molce-42-9-672){ref-type="fig"}). In addition, histological analysis revealed a significantly greater necrosis ([Fig. 2G](#f2-molce-42-9-672){ref-type="fig"}) and higher Suzuki scores ([Fig. 2H](#f2-molce-42-9-672){ref-type="fig"}) in the sections undergoing 6 h of reperfusion after 45 min of ischemia. Taken together, these findings indicate that CBR1 expression was associated with murine hepatic I/R injury.

Sulforaphane attenuates hepatic I/R injury by increasing CBR1 expression via Nrf2
---------------------------------------------------------------------------------

To confirm whether SF, an inducer of Nrf2 target genes, attenuated hepatic I/R injury by increasing CBR1 expression, we administered SF 48 h and 24 h before 45 min of hepatic ischemia and 6 h of reperfusion ([Fig. 3A](#f3-molce-42-9-672){ref-type="fig"}). Following I/R, SF-treated mice showed lower levels of AST and ALT compared with untreated mice ([Figs. 3B and 3C](#f3-molce-42-9-672){ref-type="fig"}). The expression of the inflammatory cytokines TNFα and IL-6 was also lower in treated mice, as revealed by RT-PCR ([Figs. 3D and 3E](#f3-molce-42-9-672){ref-type="fig"}). Liver Cbr1 levels were consistently elevated by SF but not significantly ([Fig. 3F](#f3-molce-42-9-672){ref-type="fig"}). Histological analysis revealed less tissue injury in SF-treated than untreated mice ([Figs. 3G and 3H](#f3-molce-42-9-672){ref-type="fig"}). Immunohistochemical analysis showed that SF administration induces Cbr1 expression ([Fig. 3I](#f3-molce-42-9-672){ref-type="fig"}). Western blot analysis showed that both CBR1 and Nrf2 expression was increased in SF-treated mice ([Figs. 3J and 3K](#f3-molce-42-9-672){ref-type="fig"}). The expression of thioredoxin (TRX) was significantly increased upon exposure to SF or I/R conditions. The expression of TRX peaked upon exposure to I/R and SF together. Expression of the oxidative stress markers HSP70 and HSP60 was increased significantly under I/R conditions and restored when treated with SF ([Figs. 3L and 3M](#f3-molce-42-9-672){ref-type="fig"}). The lipid peroxidation products 4HNE, MDA, and Acrolein increased significantly under I/R conditions, which was attenuated by SF treatment ([Figs. 3N and 3O](#f3-molce-42-9-672){ref-type="fig"}).

Luteolin increases hepatic ischemia--reperfusion injury via the Nrf2--CBR1 signaling pathway
--------------------------------------------------------------------------------------------

The administration of LT, an inhibitor of CBR1 expression, 48 h or 24 h before 45 min of hepatic ischemia and 6 h of reperfusion injury ([Fig. 4A](#f4-molce-42-9-672){ref-type="fig"}) resulted in elevated AST and ALT levels in treated than in untreated mice ([Figs. 4B and 4C](#f4-molce-42-9-672){ref-type="fig"}). RT-PCR revealed that TNFα and IL-6 expression also was higher in LT-treated mice ([Figs. 4D and 4E](#f4-molce-42-9-672){ref-type="fig"}). The CBR1 expression was dramatically lower in LT-treated mice ([Fig. 4F](#f4-molce-42-9-672){ref-type="fig"}). Additionally, histological analysis revealed a more severe damage in LT-treated than untreated mice ([Figs. 4G and 4H](#f4-molce-42-9-672){ref-type="fig"}). Immunohistochemical analysis ([Fig. 4I](#f4-molce-42-9-672){ref-type="fig"}) and western blot results showed that LT administration before I/R decreased CBR1 expression ([Figs. 4J and 4K](#f4-molce-42-9-672){ref-type="fig"}). The levels of HSP70 and HSP60, which are the oxidative stress markers, increased under I/R exposure in individuals treated with LT, while the expression of TRX was decreased by LT ([Figs. 4L and 4M](#f4-molce-42-9-672){ref-type="fig"}). Lipid peroxidation products (4HNE, MDA, and Acrolein) were elevated in all mice after I/R, with greater elevation in LT-treated mice ([Figs. 4N and 4O](#f4-molce-42-9-672){ref-type="fig"}).

Overexpressed or knockdown CBR1 is related to lipid peroxidation downstream products
------------------------------------------------------------------------------------

To further investigate the role of CBR1 expression in attenuating I/R injury, we used hepaRG cells to create a cell line overexpressing CBR1, which exhibited stable expression of CBR1. CBR1-overexpressing cells (CBR1/WT) showed a significantly high expression of CBR1. The cells with control vectors (Mock) and CBR1-overexpressing cell lines both expressed higher transcriptional levels of CBR1 under OGD/R conditions ([Fig. 5A](#f5-molce-42-9-672){ref-type="fig"}). RT-PCR analysis of this cell line after 7 h exposure to OGD/R revealed that the levels of the stress markers HSP70 and HSP60 were lower than in the parent cell line ([Fig. 5A](#f5-molce-42-9-672){ref-type="fig"}). The expression of interleukin 1 beta (IL-1β), IL-6, and TNFα also was lower in CBR1-overexpressing cells ([Fig. 5B](#f5-molce-42-9-672){ref-type="fig"}), similar to the expression of SOD1, SOD2, TRX, and TRX reductase (TRXR) ([Fig. 5C](#f5-molce-42-9-672){ref-type="fig"}). The protein levels of Nrf2 were significantly increased under OGD/R while the expression of CBR1 was diminished ([Figs. 5D and 5E](#f5-molce-42-9-672){ref-type="fig"}). We also observed a lower expression of a variety of stress-response markers (TRX, HSP70, and HSP60) in CBR1-overexpressing cells ([Figs. 5F and 5G](#f5-molce-42-9-672){ref-type="fig"}). Similar trends were also observed for the lipid peroxidation products, 4HNE, MDA, and Acrolein ([Figs. 5H and 5I](#f5-molce-42-9-672){ref-type="fig"}).

Conversely, we constructed a CBR1-knock down cell line with CBR1 siRNA, resulting in a profoundly decreased CBR1. The RT-PCR analysis revealed that cells with a lower CBR1 expression showed higher levels of damage markers (HSP70 and HSP60; [Fig. 6A](#f6-molce-42-9-672){ref-type="fig"}), pro-inflammatory cytokines (IL-1β, IL-6, and TNFα; [Fig. 6B](#f6-molce-42-9-672){ref-type="fig"}), and oxidative stress markers (SOD1, SOD2, TRX, and TRXR; [Fig. 6C](#f6-molce-42-9-672){ref-type="fig"}). The nuclear levels of Nrf2 were not changed by CBR1 siRNA; however, they were increased by OGD/R ([Figs. 6D and 6E](#f6-molce-42-9-672){ref-type="fig"}). The expression of oxidative stress markers (TRX, HSP70, and HSP60; [Figs. 6F and 6G](#f6-molce-42-9-672){ref-type="fig"}) and lipid peroxidation products (4HNE, MDA, and Acrolein) was elevated in CBR knockdown cells ([Figs. 6H and 6I](#f6-molce-42-9-672){ref-type="fig"}).

Human CBR1 expression is upregulated by Nrf2 during orthotopic living-donor liver transplantation
-------------------------------------------------------------------------------------------------

To investigate the role of CBR1 in I/R injury in humans, we harvested two liver biopsies from each of the seven patients; one immediately after incision for use as a control and the other after reperfusion ([Fig. 7A](#f7-molce-42-9-672){ref-type="fig"}). Consistent with our previous results in mice, human CBR1 was upregulated after reperfusion compared with the control ([Fig. 7B](#f7-molce-42-9-672){ref-type="fig"}). Western blot analysis of the nuclear and cytosolic fractions of cell lysates revealed elevated expression of Nrf2 and CBR1 during living-donor liver transplantation ([Fig. 7C](#f7-molce-42-9-672){ref-type="fig"}). Quantitative western blot analysis of Nrf2 and CBR1 expression showed consistent results ([Fig. 7D](#f7-molce-42-9-672){ref-type="fig"}).

DISCUSSION
==========

Hepatic I/R injury leads to severe liver damage and is a significant cause of liver transplantation failure ([@b37-molce-42-9-672]). Prevention and amelioration of I/R injury is an unmet clinical need. The current paradigm of hepatic I/R injury is based on two apparently separate events involving cell damage in the ischemic phase and inflammation during the reperfusion phase ([@b17-molce-42-9-672]). While ischemic insult is readily tolerated by the liver, the reperfusion-induced inflammatory response is the main culprit in liver destruction ([@b13-molce-42-9-672]; [@b14-molce-42-9-672]). Thus, recent efforts to develop therapeutic agents have focused on the direct inhibition of inflammation and cell death during the reperfusion stage. However, the limited therapeutic effects observed in rodent models cannot be translated to humans, and the clinical benefits of this approach have yet to be established unequivocally.

CBR1 is known to increase cell survival under oxidative stress by preventing the formation of lipid peroxidation products ([@b5-molce-42-9-672]; [@b34-molce-42-9-672]). In this study, our results indicate that Nrf2 induced CBR1 transcription during both OGD/R and hydrogen peroxide treatment, and hepatic I/R injuries in mice and humans. Previous studies showed the chemically induced Nrf2 promoted CBR1 expressions, but not in physiological conditions, especially under liver I/R injury. We showed that pre-treatment with SF, an inducer of CBR1 expression ([@b41-molce-42-9-672]) decreased the expression of the liver function enzymes (AST and ALT) and significantly decreased I/R injury-related pathological changes in liver tissues. On the other hand, LT, a known inhibitor of Nrf2 decreased the CBR1 expression in liver tissues exposed to more severe I/R injury. As TRX is a known target for Nrf2, the protein levels of TRX were increased when mice were treated with SF. Conversely, LT exposure decreased the levels TRX suggesting that SF and LT worked as Nrf2 regulators in the mouse model of liver I/R injury.

Western blot analysis showed that the expression of oxidative stress markers (TRX, HSP70, and HSP60) and lipid peroxidation products (4HNE, MDA, and Acrolein) was significantly lower in cells overexpressing CBR1. CBR1 knockdown elevated the levels of oxidative stress proteins compared with the parental cell line. We also observed that human CBR1 was overexpressed during orthotropic living-donor liver transplantation via Nrf2.

Studies showed that overexpressed CBR1 attenuated hepatic cell death against oxidative stress by reducing ROS within cells and such mechanisms were partially regulated by Nrf2 system ([@b8-molce-42-9-672]; [@b27-molce-42-9-672]; [@b35-molce-42-9-672]). In addition, we confirmed that CBR1 transcription was increased during hepatic I/R injury via Nrf2 following the binding of Nrf2 to the ARE sequence 5′-TGACXXXGC-3′ within the CBR1 promoter region. The human ARE sequence containing the Nrf2 binding site is 5′-[TGAC]{.ul}TTT[GC]{.ul}A-3′, which is located −252 bp upstream of the CBR1 start codon ([@b30-molce-42-9-672]). Nrf2 stabilization and activation of the transcription factors were observed under OGD/R conditions as well as hydrogen peroxide-induced stress. The results indicated that physiological conditions of oxidative stress during I/R injuries also stabilized Nrf2 and increased the cellular levels of CBR1.

LT is known as an antioxidant, but it is also known as an inhibitor of Nrf2. In other study, LT inhibited Nrf2/ARE pathways resulting in a negative regulation of cancer cells ([@b39-molce-42-9-672]). In addition, several cancer studies suggested LT acted as a chemotherapeutic agent by suppressing Nrf2 pathways in cancer and facilitated the therapeutic suppression of tumor growth ([@b2-molce-42-9-672]). Apparently, LT reduces oxidative stress not by directly increasing the antioxidant proteins but via regulation of inflammation ([@b7-molce-42-9-672]; [@b42-molce-42-9-672]). Indeed, our data showed that treating LT under basal conditions significantly decreased the level of inflammatory cytokine IL-6. Therefore, LT can be partially beneficial in restoring liver injuries by suppressing the pro-inflammatory signals even though it suppresses Nrf2-regulated antioxidant genes discussed in our study.

We confirmed that CBR1 expression is regulated by Nrf2 in human liver. Numerous studies have provided substantial evidence supporting the critical role of ROS in hepatic I/R injury ([@b4-molce-42-9-672]; [@b6-molce-42-9-672]; [@b10-molce-42-9-672]; [@b37-molce-42-9-672]). Therefore, strategies to inhibit ROS production and enhance ROS scavenging have been suggested as therapeutic approaches. Nrf2, a transcription factor mediating the expression of many endogenous antioxidants, is known to play an essential role in protecting cells against oxidative stress ([@b12-molce-42-9-672]; [@b15-molce-42-9-672]; [@b20-molce-42-9-672]; [@b25-molce-42-9-672]; [@b31-molce-42-9-672]; [@b32-molce-42-9-672]). Recent studies have shown that Nrf2 also exerts anti-inflammatory response through regulation of NADPH oxidase ([@b22-molce-42-9-672]) and pro-inflammatory signaling ([@b21-molce-42-9-672]). Several reports have revealed that Nrf2-null mice are highly susceptible to hepatic injuries induced by chemicals ([@b26-molce-42-9-672]), alcohols ([@b24-molce-42-9-672]), high-fat diet ([@b29-molce-42-9-672]), methionine/choline-deficient diet ([@b3-molce-42-9-672]), and cytokines ([@b21-molce-42-9-672]), indicating that Nrf2 protects the liver via multiple cytoprotective pathways.

Our study demonstrated that Nrf2 increases CBR1 expression and attenuates hepatic cell death under I/R conditions. The attenuated cell death is attributed to the ability of CBR1 to reduce oxidative stress, including lipid peroxidation ([@b5-molce-42-9-672]). Therefore, we propose that CBR1 is one of the anti-oxidative and anti-apoptotic molecules regulated by Nrf2.

Oxidative-stress--induced hepatic senescence is one of the primary causes of severe liver I/R injury ([@b40-molce-42-9-672]). CBR1 deficiency aggravates oxidative stress, inflammatory response, and liver damage. We observed that overexpression of CBR1 before ischemia significantly suppressed the expression of oxidative stress enzymes and the production of lipid peroxidation products. The development of a specific and practical CBR1 activator represents a possible strategy for protection against hepatic I/R injury ([Fig. 8](#f8-molce-42-9-672){ref-type="fig"}).

In this study, we found that Nrf2-CBR1 regulation was robustly activated under oxidative stress conditions in normal hepatocyte cell lines, hepatic I/R animal model, and clinical samples. We found that the up-regulation of Nrf2-CBR1 system attenuated I/R injury in the liver while the down-regulation of Nrf2-CBR1 system severely damaged the liver. These findings suggest that Nrf2-CBR1 plays a protective role in living-donor liver transplantation.
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![Temporal regulation of CBR1 expression by Nrf2 with OGD/R and hydrogen peroxide\
(A--D) CBR1 is upregulated temporally by Nrf2 during OGD/R and hydrogen peroxide treatment. Western blot images and densitometric quantitation of the blots. (E) Schematic diagram of the promoter regions of human CBR1, including full-length ARE1 and ARE2 and an ARE1 mutant. (F and G) Luciferase reporter assay with OGD/R and hydrogen peroxide treatment. (H) CBR1 immunofluorescent staining. Normal hepatic hepaRG cells were stained with anti-CBR1 monoclonal antibody. Blue, DAPI; Green, human CBR1. Data are representative of five independent experiments. Data are presented as the mean ± SD. Respective comparison was indicated by a line and *P* value. n.s., not significant.](molce-42-9-672f1){#f1-molce-42-9-672}

![CBR1 expression increased during hepatic I/R in a mouse model\
(A) Schematic outline of mice experiments. (B) AST and (C) ALT after ischemic period for 45 min followed by 2 h, 6 h, and 24 h of reperfusion. Relative expression of (D) murine *TNFα*, (E) murine *IL-6*, and (F) murine *Cbr1* measured by qRT-PCR. Expression levels are normalized to *Gapdh*. (G) Liver histology and (H) quantification of histologic tissue injury using the Suzuki Scoring Index (0--4). The necrosis area is outlined by dotted lines. Comparison is indicated by a line and *P* value. n.s., not significant. n = 6 per group.](molce-42-9-672f2){#f2-molce-42-9-672}

![Administration of CBR1 inducer SF attenuates hepatic cell death\
(A) Schematic outline of SF administration of mice. Measurement of (B) ALT and (C) AST. Relative expression of (D) murine *TNFα*, (E) *IL-6*, and (F) *Cbr1* measured by qRT-PCR. Expression levels are normalized to *Gapdh*. (G) Liver histology and (H) quantification of liver injury. (I) Immunohistochemistry of murine CBR1. (J and K) Protein expression of Nrf2 and CBR1 and relative density. (L and M) Western blot analysis of oxidative stress markers (TRX, HSP70, and HSP60) and relative density. (N and O) Western blot of lipid peroxidation products (4HNE, MDA, and Acrolein) and relative density. Protein levels were normalized to Actin, except for Nrf2 which was normalized to TBP. The levels of other compounds were normalized to matching control group. Veh., vehicle; White bar, vehicle-treated; Black bar, SF-treated. Comparison is indicated by a line and *P* value. n.s., not significant. n = 6--12 per group.](molce-42-9-672f3){#f3-molce-42-9-672}

![Administration of the CBR1 reducer LT increases hepatic ischemia--reperfusion injury and hepatic cell death\
(A) Schematic outline of LT administration of mice. Serum measurement of (B) AST and (C) ALT. Relative expression of (D) murine *TNFα*, (E) *IL-6*, and (F) *Cbr1* measured by qRT-PCR. Expression levels are normalized to *Gapdh*. (G) H&E staining of liver injury and (H) histology score of LT-treated mice. (I) Immunohistochemistry of CBR1. (J and K) Protein expression of Nrf2 and CBR1 and relative density. (L and M) Western blot analysis of oxidative stress markers (TRX, HSP70, and HSP60) and relative density. (N and O) Western blot of lipid peroxidation products (4HNE, MDA, and Acrolein) and relative density. Protein levels were normalized to Actin, except for Nrf2 which was normalized to TBP. The levels of other compounds were normalized to matching control group. Veh., vehicle; White bar, vehicle-treated; Black bar, LT-treated. Comparison is indicated by a line and *P* value. n.s., not significant. n = 6--12 per group.](molce-42-9-672f4){#f4-molce-42-9-672}

![Gain-of-function study of CBR1 in normal hepatocyte cells under hydrogen peroxide treatment\
(A) Transcription levels of *CBR1* and oxidative stress markers (*HSP70* and *HSP60*) in mock transfected cells and a CBR1-overexpressing stable cell line under OGD/R. (B) Fold change in inflammatory cytokines (*IL-1β*, *IL-6*, and *TNFα*) in mock control vs CBR1-overexpressing cells. (C) Expression of antioxidant enzymes (*SOD1*, *SOD2*, *TRX*, and *TRXR*) in CBR1-overexpressing cells under OGD/R. (D and E) Western blot analysis of Nrf2 and CBR1 with relative density. (F and G) Oxidative stress markers (TRX, HSP70, and HSP60) with relative density. (H and I) Lipid peroxidation products (4HNE, MDA, and Acrolein) with relative density. Protein levels were normalized to Actin, except for Nrf2 which was normalized to TBP. The levels of other compounds were normalized to matching control group. Cont., control; White bar, Mock-treated; Black bar, CBR1/WT. Comparison is indicated by a line and *P* value. n.s., not significant. n = 10 per group.](molce-42-9-672f5){#f5-molce-42-9-672}

![Loss-of-function study of CBR1 in normal hepatocyte cells under hydrogen peroxide treatment\
(A) Transcription levels of *CBR1* and oxidative stress markers with control siRNA and CBR1 siRNA under OGD/R. (B) Fold change in inflammatory cytokine expression in control and CBR1 siRNA cells. (C) Expression of antioxidant enzymes in CBR1 siRNA cells under OGD/R. (D and E) Western blot analysis of Nrf2 and CBR1 with relative density. (F and G) Oxidative stress markers (TRX, HSP70, and HSP60) with relative density. (H and I) Lipid peroxidation products (4HNE, MDA, and Acrolein) with relative density. Protein levels were normalized to Actin, except for Nrf2 which was normalized to TBP. The levels of other compounds were normalized to matching control group. Cont., control; White bar, scrambled siRNA-treated; Black bar, CBR1 siRNA-treated. Comparison is indicated by a line and *P* value. n.s., not significant. n = 10 per group.](molce-42-9-672f6){#f6-molce-42-9-672}

![CBR1 expression in biopsies of transplanted human liver\
(A) Liver specimens were harvested at the conclusion of CIT during the preparation of living-donor liver allograft and during reperfusion after warm ischemia and reperfusion, immediately before suturing of the abdomen following drain placement. WIT, warm ischemia time; RT, reperfusion time. (B) *CBR1* mRNA level by RT-PCR. (C) Nrf2 and CBR1 proteins in 7 patients (P1--P7; one representative blot of 3 is shown) as assessed by western blot analysis and (D) quantification of CBR1 expression by density. Protein levels were normalized to Actin, ecxept for Nrf2 which was normalized to TBP. White bar, before I/R; Black bar, after I/R. Comparison is indicated by a line and *P* value. n.s., not significant.](molce-42-9-672f7){#f7-molce-42-9-672}

![Graphic summary of the CBR1 function under hepatic ischemia reperfusion injury\
CBR1 is transcriptionally induced by Nrf2 during liver I/R injury. Higher expression of CBR1 relieves oxidative stress and lipid peroxidation in the liver during I/R injury while suppressed CBR1 increases the damage. As human CBR1 is upregulated by Nrf2 during liver transplantation, CBR1 induction can be a therapeutic strategy for relieving liver I/R injury during liver transplantation.](molce-42-9-672f8){#f8-molce-42-9-672}

###### 

Patients characteristics

  Patient No.   Donor age (y)   Recipient age (y)   MELD          CIT (min)      WIT (min)      RT (min)
  ------------- --------------- ------------------- ------------- -------------- -------------- ---------------
  1             26              49                  6             96             47             143
  2             26              55                  7             75             33             108
  3             27              57                  9             92             37             129
  4             28              59                  8             99             33             132
  5             29              63                  7             105            58             163
  6             33              65                  10            63             29             92
  7             32              51                  10            64             44             108
                28.71 ± 1.06    58.43 ± 2.03        8.14 ± 0.59   84.86 ± 6.53   40.14 ± 3.83   125.00 ± 9.13

Values are presented as number only or mean ± SD.

MELD score, model for end-stage liver disease score; CIT, cold ischemia time; WIT, warm ischemia time; RT, reperfusion time.

###### 

Human and mouse primers

                      Sense or Antisense      Sequence (5′--3′)
  ------------------- ----------------------- ----------------------------------------------------------------------------------------
  Human                                       
   *GAPDH*            Sense                   ACAGTTGCCATGTAGACC
                      Antisense               TTGAGCACAGGGTACTTTA
   *CBR1*             Sense                   ACAAATTTCTTTGGTACCCG
                      Antisense               TAGATACGTTCACCACTCTC
   *HSPD1 (HSP60)*    Sense                   CGTCTTGAATAGGCTAAAGG
                      Antisense               TGAACATCTTCAAGATTCAG
   *HSPA14 (HSP70)*   Sense                   AGGAACATCCTTATCTCTCAG
                      Antisense               GATCTTTGGAACTCAGAAGC
   *SOD1*             Sense                   GAGCAGAAGGAAAGTAATGG
                      Antisense               GATTAAAGTGAGGACCTGC
   *SOD2*             Sense                   ATCATACCCTAATGATCCCAG
                      Antisense               AGGACCTTATAGGGTTTTCAG
   *TXN1*             Sense                   CTTTGGATCCATTTCCATCG
                      Antisense               GCAACATCATGAAAGAAAGG
   *TXNRD1*           Sense                   AGACAGTTAAGCATGATTGG
                      Antisense               AATTGCCCATAAGCATTCTC
   *TNFα*             Sense                   AGGCAGTCAGATCATCTTC
                      Antisense               TTATCTCTCAGCTCCACG
   *IL-6*             Sequence not provided   Hs_IL6_1\_SG QuantiTect Primer Assay (Qiagen; product No. 249900, cat No. QT00083720)
   *IL-1β*            Sequence not provided   Hs_IL1B_1\_SG QuantiTect Primer Assay (Qiagen; product No. 249900, cat No. QT00021385)
  Mouse                                       
   *Gapdh*            Sense                   AGGTCGGTGTGAACGGATTTG
                      Antisense               TGTAGACCATGTAGTTGAGGTCA
   *Cbr1*             Sense                   CCTCTAATAAAACCCCAAGG
                      Antisense               CTATTAGGCCAACCTTCTTC
   *TNFα*             Sense                   CTATGTCTCAGCCTCTTCTC
                      Antisense               CATTTGGGAACTTCTCATCC
   *IL-6*             Sequence not provided   Mm_Il6_1\_SG QuantiTect Primer Assay (Qiagen; product No. 49900, cat No. QT00098875)
   *IL-1β*            Sequence not provided   Mm_Il1b_2\_SG QuantiTect Primer Assay (Qiagen; product No. 249900, cat No.QT01048355)
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